Breaking News
December 15, 2018 - Research offers hope for patients with serious bone marrow cancer
December 15, 2018 - Link between poverty and obesity is only about 30 years old, study shows
December 15, 2018 - Mass spectrometry throws light on old case of intentional heavy metal poisoning
December 15, 2018 - BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
December 15, 2018 - Study finds that in treating obesity, one size does not fit all
December 15, 2018 - Tenacity and flexibility help maintain psychological well-being, mobility in older people
December 15, 2018 - Study reveals role of brain mechanism in memory recall
December 15, 2018 - High levels of oxygen encourage the brain to remain in deep, restorative sleep
December 15, 2018 - Experimental HIV vaccine strategy works in non-human primates, research shows
December 15, 2018 - Genetically modified pigs could limit replication of classical swine fever virus, study shows
December 15, 2018 - FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
December 15, 2018 - Cost and weight-loss potential matter most to bariatric surgery patients
December 15, 2018 - Cancer Research UK and AstraZeneca open new Functional Genomics Centre
December 15, 2018 - New research lays out potential path for treatment of Huntington’s disease
December 15, 2018 - Prestigious R&D 100 Award presented to Leica Microsystems
December 15, 2018 - Study shows septin proteins detect and kill gut pathogen, Shigella
December 15, 2018 - Study sheds new light on disease-spreading mosquitoes
December 15, 2018 - 2017 Saw Slowing in National Health Care Spending
December 15, 2018 - Monitoring movement reflects efficacy of mandibular splint
December 15, 2018 - Study supports BMI as useful tool for assessing obesity and health
December 15, 2018 - Self-guided, internet-based therapy platforms effectively reduce depression
December 15, 2018 - Organically farmed food has bigger climate impact than conventional food production
December 15, 2018 - Faster, cheaper test has potential to enhance prostate cancer evaluation
December 15, 2018 - Researchers study abnormal blood glucose levels of patients after hospital discharge
December 15, 2018 - Swedish scientists explore direct association of dementia and ischemic stroke deaths
December 15, 2018 - Study finds 117% increase in number of dementia sufferers in 26 years
December 15, 2018 - Eczema Can Drive People to Thoughts of Suicide: Study
December 15, 2018 - Link between neonatal vitamin D deficiency and schizophrenia confirmed
December 15, 2018 - Nurse denied life insurance because she carries naloxone
December 15, 2018 - Ritalin drug affects organization of pathways that build brain networks used in attention, learning
December 15, 2018 - Research pinpoints two proteins involved in creation of stem cells
December 15, 2018 - Gut bacteria may modify effectiveness of anti-diabetes drugs
December 15, 2018 - Breast cancer protection from pregnancy begins many decades later, study finds
December 15, 2018 - How often pregnant women follow food avoidance strategy to prevent allergy in offspring?
December 15, 2018 - Using machine learning to predict risk of developing life-threatening infections
December 15, 2018 - How imaginary friends could boost children’s development
December 15, 2018 - Folate deficiency creates more damaging chromosomal abnormalities than previously known
December 15, 2018 - Study provides new insights into molecular mechanisms underlying role of amyloid in Alzheimer’s disease
December 15, 2018 - For the asking, a check is in the mail to help pay for costly drugs
December 15, 2018 - UA scientists uncover biological processes leading to rare brain disorder in babies
December 15, 2018 - The largest database on industrial poisons
December 15, 2018 - ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients
December 15, 2018 - Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
December 15, 2018 - Left ventricular noncompaction – Genetics Home Reference
December 15, 2018 - Children’s sleep not significantly affected by screen time, new study finds
December 15, 2018 - When should dementia patients stop driving? A new guidance for clinicians
December 15, 2018 - Researchers use INTEGRA’s VIAFLO 96/384 to streamline the experimental workflow
December 15, 2018 - Researchers discover protein involved in nematode stress response
December 15, 2018 - Cancer patients have greater risk of developing shingles, study shows
December 14, 2018 - UAlberta scientists identify biomarkers for detecting Alzheimer’s disease in saliva samples
December 14, 2018 - Study uncovers link between tube travel and spread of flu-like illnesses
December 14, 2018 - Caffeine plus another compound in coffee may fight Parkinson’s disease
December 14, 2018 - GW researchers review studies on treatments for prurigo nodularis
December 14, 2018 - Lack of peds preventive care ups unplanned hospital admissions
December 14, 2018 - Miscarriage: When Language Deepens Pain
December 14, 2018 - New method helps better understand pathological development of ALS
December 14, 2018 - Intellectually active lifestyle confers protection against neurodegeneration in Huntington’s patients
December 14, 2018 - Mammalian collagen nanofibrils become stronger and tougher with exercise
December 14, 2018 - Considerable Morbidity, Mortality Due to Animal Encounters
December 14, 2018 - Researchers find inhibiting one protein destroys toxic clumps seen in Parkinson’s disease
December 14, 2018 - How early physical therapy can lessen the long-term need for opioids
December 14, 2018 - Depression, suicide rates highest in Mountain West states
December 14, 2018 - New model could cure the potential to underestimate how quickly diseases spread
December 14, 2018 - Exercise-induced hormone activates cells critical for bone remodeling in mice
December 14, 2018 - Researchers discover new mechanism behind spread of malignant pleural mesothelioma
December 14, 2018 - Health Tip: Celebrate a Healthier Holiday
December 14, 2018 - Scalpel-free surgery enhances quality of life for Parkinson’s patients, study finds
December 14, 2018 - Early physical therapy can reduce risk, amount of long-term opioid use | News Center
December 14, 2018 - Genetic marker, predictor of early relapse in common childhood cancer discovered
December 14, 2018 - Study could lead to a potential new way of treating sepsis
December 14, 2018 - New protein complex helps embryonic stem cells to maintain their indefinite potential
December 14, 2018 - Salk professor receives $1.8 million from NOMIS Foundation for research on mechanisms to promote health
December 14, 2018 - New discovery will improve the safety and predictability of CRISPR
December 14, 2018 - Geneticists discover how sex-linked disorders arise
December 14, 2018 - New method to visualize small-molecule interactions inside cells
December 14, 2018 - Study describes mechanism that makes people more vulnerable to hunger-causing stimuli
December 14, 2018 - Chronic opioid therapy associated with increased healthcare spending and hospital stays
December 14, 2018 - Blood Types
December 14, 2018 - Obesity linked to increased risk of early-onset colorectal cancer
December 14, 2018 - Blood test helps identify distinct molecular signatures in children with cystic fibrosis
Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

image_pdfDownload PDFimage_print

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) that were reported today in the New England Journal of Medicine.

The international study, led by MSK medical oncologist and world-renowned kidney cancer expert Robert Motzer, MD, compared the combination of the two immunotherapies against sunitinib alone in people with advanced renal cell carcinoma (RCC) who had not yet received treatment. Researchers found that the combination of the immunotherapies ipilimumab and nivolumab extended overall survival, and objective response rates were significantly higher with the combination than with sunitinib alone.

“We have seen a significant improvement in overall survival,” said Dr. Motzer, lead author and principal investigator of the study. “This immunotherapy combination offers a completely different mechanism of action, and it introduces a new type of therapy in this setting. One earlier trial gave us a hint of potential, but this is the first time we have been able to demonstrate a survival benefit in a first-line therapy for renal cell carcinoma.”

In the randomized phase III trial, a total of 1,096 people who’d had no prior treatment were randomly assigned to treatment at 175 sites in 28 countries. There were 550 people treated with the nivolumab plus ipilimumab combination and 546 treated with sunitinib, the current standard of care. Researchers found a significant difference in overall survival favoring the ipilimumab and nivolumab combination, with an 18-month overall survival rate of 78 percent versus 68 percent with sunitinib alone.

This study was also designed for a formal statistical comparison between the sunitinib group and the combination group in producing objective responses (meaning substantial tumor shrinkage). Those receiving the combination also had a higher objective response. In addition, 9 percent of people in the combination trial had a complete response (with no evidence of the tumor remaining) versus 1 percent of those who received sunitinib alone.

Ipilimumab and nivolumab are part of a class of drugs called immune checkpoint inhibitors, which unleash the immune system to attack cancer. The immune system has several checkpoints in place to avoid an overreaction. Ipilimumab works by blocking the CTLA-4 checkpoint, a molecular brake that stops T cells from becoming fully and persistently activated. Similarly, nivolumab prevents the molecule PD-L1, expressed by tumors, from binding to T cells and deactivating them.

Because immunotherapy drugs work differently than targeted therapies, side effects can be significant.

Implications for People with RCC

Kidney cancer is notoriously difficult to treat. RCC, the most common form of the disease, is often diagnosed when it has already spread to other organs. Until recently, people with RCC had few therapeutic options. For years, oncologists have had very limited choices for how to treat people with metastatic RCC. The targeted therapy sunitinib was approved in 2006, based on studies led by Dr. Motzer at MSK. Since then, it has remained the standard of care as initial treatment for this disease.

More than 330,000 people are diagnosed with RCC every year, and the disease causes more than 140,000 deaths worldwide annually. It’s also particularly aggressive: At the time of diagnosis approximately 30 percent of people have metastatic disease, which means the cancer has already spread to other organs, and about one-third of people whose disease is confined to the kidney will relapse.

“This trial has produced practice-changing results in kidney cancer and represents another important step in the clinical trials program at MSK. We believe the results of this trial will now make this combination the standard of care in advanced metastatic kidney cancer,” said Dr. Motzer.

Immunotherapy at MSK

Cancer immunotherapy was born at MSK over a century ago. Since then, MSK scientists have led the effort to develop immune-based treatments for cancer. MSK has been at the epicenter of discoveries in the field, and the institution’s work is bringing exciting new treatment options to people with cancer.

The nivolumab and ipilimumab combination was developed at MSK by cancer immunologist Jedd Wolchok, MD, PhD. Positive results were found as a treatment for melanoma, and the combination now serves as the standard of care in that disease.

MSK has extensive experience in using immunotherapy to treat people with melanoma, kidney cancer, lung cancer, and others, as well as in handling immune-related side effects. On November 23, 2015, the Food and Drug Administration approved nivolumab for the treatment of advanced RCC. Although nivolumab was already used to treat melanoma and lung cancer, this marked the first time the FDA had approved a checkpoint inhibitor for the treatment of kidney cancer.​

Source:

https://www.mskcc.org/press-releases/pivotal-results-phase-iii-trial-show-combination-ipilimumab-and-nivolumab-increases-overall-survival-people-kidney

About author

Related Articles